CDMO(의약품 수탁개발제조기관) 아웃소싱 시장 : 규모, 점유율, 성장, 산업 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of Contract Development & Manufacturing Organization (CDMO) Market

The global Contract Development & Manufacturing Organization (CDMO) market was valued at USD 199.27 billion in 2025 and is expected to grow from USD 214.95 billion in 2026 to USD 419.93 billion by 2034, registering a CAGR of 8.7% during the forecast period. The market is expanding rapidly as pharmaceutical and biotechnology companies increasingly outsource drug development, manufacturing, analytical testing, packaging, and regulatory services to specialized CDMOs. Outsourcing enables drug developers to reduce capital investment, accelerate commercialization timelines, improve operational efficiency, and gain access to advanced manufacturing technologies.

Growing demand for biologics, cell and gene therapies, high-potency APIs, sterile injectables, and mRNA-based products is further strengthening the need for experienced CDMO partners with specialized facilities and regulatory expertise. The market is also benefiting from increasing investments in research and development, rising pharmaceutical pipelines, and the growing number of clinical trials worldwide.

Leading companies such as Lonza, Thermo Fisher Scientific Inc., Catalent, Samsung Biologics, and WuXi Biologics continue expanding their manufacturing capacities, acquiring specialized facilities, and launching integrated development platforms to strengthen their global presence.

Market Trends

A major trend shaping the CDMO market is the growing preference for integrated end-to-end outsourcing platforms. Pharmaceutical companies increasingly prefer a single partner capable of handling formulation development, analytical testing, clinical manufacturing, commercial production, packaging, and regulatory support. This integrated approach reduces project complexity, shortens development timelines, and improves supply chain efficiency.

The growing adoption of biologics manufacturing, continuous manufacturing technologies, digital quality management systems, and AI-driven process optimization is also transforming the industry. Companies are investing heavily in advanced manufacturing technologies to improve production efficiency and regulatory compliance.

Market Drivers

The primary driver of market growth is the increasing outsourcing of pharmaceutical manufacturing by biotech and pharmaceutical companies. Developing modern manufacturing facilities requires enormous investments, highly skilled personnel, and strict regulatory compliance. Outsourcing allows companies to focus on drug discovery and commercialization while reducing operational risks.

The rapid expansion of biologics, biosimilars, oncology therapies, vaccines, antibody-drug conjugates (ADCs), and personalized medicines has significantly increased demand for specialized CDMO services. Growing clinical trial activities and rising demand for flexible manufacturing capacity continue supporting market expansion.

Market Restraints

Despite strong growth prospects, the market faces challenges due to the extremely high capital investment required to establish advanced pharmaceutical manufacturing facilities. Building compliant production plants, validating manufacturing processes, and obtaining regulatory approvals require substantial financial resources and long development timelines.

In addition, maintaining Good Manufacturing Practice (GMP) standards and meeting global regulatory requirements increases operational costs, particularly for smaller service providers.

Market Opportunities

The emergence of advanced biologics, cell and gene therapies, viral vectors, mRNA products, peptide therapeutics, and high-potency APIs presents significant opportunities for CDMOs. These complex therapies require highly specialized development and manufacturing capabilities that many pharmaceutical companies prefer to outsource.

Increasing strategic partnerships, mergers, acquisitions, and facility expansions across Asia Pacific, North America, and Europe are expected to create new revenue opportunities throughout the forecast period.

Market Challenges

One of the biggest challenges for CDMOs is maintaining strict regulatory compliance across multiple international markets. Manufacturing failures, contamination risks, technology transfer delays, documentation errors, and regulatory inspections can significantly impact production schedules and company reputation.

Additionally, rising operational costs, supply chain disruptions, and increasing competition among global CDMO providers continue creating pressure on profit margins.

Segmentation Analysis

Based on service, the contract manufacturing segment dominated the market in 2025 as pharmaceutical companies increasingly outsourced commercial-scale manufacturing, API production, biologics manufacturing, sterile fill-finish, and packaging operations. The contract development segment is expected to witness faster growth due to increasing demand for formulation development, analytical testing, process optimization, and regulatory support.

By molecule type, small molecules accounted for the largest market share and are projected to represent 52.5% of the market in 2026, supported by strong demand for generic drugs, specialty medicines, and oncology products. Meanwhile, the biologics segment is expected to record strong growth as biologic therapies continue expanding worldwide.

Based on therapeutic area, the oncology segment dominated the market due to the large number of cancer drug candidates requiring complex manufacturing and specialized production capabilities. Oncology is projected to account for 25.5% of the global market in 2026.

Regional Outlook

North America dominated the global CDMO market with a value of USD 69.06 billion in 2025, supported by the strong presence of global pharmaceutical companies, advanced manufacturing infrastructure, and continuous investments in biologics production. The U.S. market is projected to reach USD 66.78 billion by 2026, remaining the largest national market.

Europe is projected to reach USD 56.47 billion in 2026, driven by stringent GMP standards, advanced biologics manufacturing capabilities, and the presence of numerous specialized CDMOs. Germany and the U.K. remain key contributors to regional growth.

Asia Pacific is expected to reach USD 56.30 billion in 2026, supported by expanding pharmaceutical manufacturing, cost-efficient production capabilities, growing domestic drug demand, and increasing investments across China, India, Japan, South Korea, and Singapore. China and India continue strengthening their global positions as preferred outsourcing destinations.

The Rest of the World is projected to experience moderate growth, supported by increasing investments in pharmaceutical manufacturing across Latin America, the Middle East, and Africa.

Competitive Landscape

The global CDMO market remains highly competitive, with major companies continuously investing in manufacturing expansion, advanced biologics capabilities, and integrated service platforms. Industry leaders are strengthening their competitive positions through acquisitions, strategic collaborations, digital manufacturing technologies, and expansion into emerging pharmaceutical markets.

Companies are increasingly focusing on biologics manufacturing, sterile injectable production, viral vectors, mRNA technologies, high-potency APIs, and integrated development services to meet the growing outsourcing requirements of global pharmaceutical and biotechnology companies.

Conclusion

The global Contract Development & Manufacturing Organization (CDMO) market is positioned for sustained long-term growth, increasing from USD 199.27 billion in 2025 to USD 214.95 billion in 2026, and projected to reach USD 419.93 billion by 2034. Rising pharmaceutical outsourcing, expanding biologics pipelines, growing demand for advanced therapies, and continuous technological innovation will remain the primary drivers of market expansion. As pharmaceutical companies increasingly rely on specialized manufacturing partners to improve efficiency and reduce development costs, CDMOs with integrated capabilities, regulatory expertise, and advanced manufacturing infrastructure will continue strengthening their global market leadership.

Segmentation By Service, Molecule Type, Therapeutic Area, and Region

By Service * Contract Manufacturing

• API Manufacturing
• Finished Product
• Solid Dosage Forms
• Injectables
• Others
  • Packaging
• Contract Development
  • Formulation Development
  • Process Development & Scale-up
  • Analytical Method Development & Validation
  • Stability Testing
  • CMC & Regulatory Development Support
  • Others

By Molecule Type * Small Molecules

• Biologics
• Cell & Gene Therapies
• Others

By Therapeutic Area * Oncology

• Infectious Diseases
• Neurology
• Cardiology
• Immunology & Inflammation
• Metabolic Disorders
• Others

By Region * North America (By Service, Molecule Type, Therapeutic Area, and Country)

• U.S.
• Canada
• Europe (By Service, Molecule Type, Therapeutic Area, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Service, Molecule Type, Therapeutic Area, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Rest of the World ( By Service, Molecule Type, Therapeutic Area, and Country/Sub-region)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Advancements in Contract Development & Manufacturing Organization (CDMO)
• 4.2. Overview of Regulatory Scenario, By Key Countries/Regions
• 4.3. Key Industry Developments - (Mergers, Acquisitions, & Partnerships, etc.)

5. Global Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Service
  • 5.1.1. Contract Manufacturing
    • 5.1.1.1. API Manufacturing
    • 5.1.1.2. Finished Product
      • 5.1.1.2.1. Solid Dosage Forms
      • 5.1.1.2.2. Injectables
      • 5.1.1.2.3. Others
    • 5.1.1.3. Packaging
  • 5.1.2. Contract Development
    • 5.1.2.1. Formulation Development
    • 5.1.2.2. Process Development & Scale-up
    • 5.1.2.3. Analytical Method Development & Validation
    • 5.1.2.4. Stability Testing
    • 5.1.2.5. CMC & Regulatory Development Support
    • 5.1.2.6. Others
• 5.2. Market Analysis, Insights and Forecast - By Molecule Type
  • 5.2.1. Small Molecules
  • 5.2.2. Biologics
  • 5.2.3. Cell & Gene Therapies
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 5.3.1. Oncology
  • 5.3.2. Infectious Diseases
  • 5.3.3. Neurology
  • 5.3.4. Cardiology
  • 5.3.5. Immunology & Inflammation
  • 5.3.6. Metabolic Disorders
  • 5.3.7. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Service
  • 6.1.1. Contract Manufacturing
    • 6.1.1.1. API Manufacturing
    • 6.1.1.2. Finished Product
      • 6.1.1.2.1. Solid Dosage Forms
      • 6.1.1.2.2. Injectables
      • 6.1.1.2.3. Others
    • 6.1.1.3. Packaging
  • 6.1.2. Contract Development
    • 6.1.2.1. Formulation Development
    • 6.1.2.2. Process Development & Scale-up
    • 6.1.2.3. Analytical Method Development & Validation
    • 6.1.2.4. Stability Testing
    • 6.1.2.5. CMC & Regulatory Development Support
    • 6.1.2.6. Others
• 6.2. Market Analysis, Insights and Forecast - By Molecule Type
  • 6.2.1. Small Molecules
  • 6.2.2. Biologics
  • 6.2.3. Cell & Gene Therapies
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 6.3.1. Oncology
  • 6.3.2. Infectious Diseases
  • 6.3.3. Neurology
  • 6.3.4. Cardiology
  • 6.3.5. Immunology & Inflammation
  • 6.3.6. Metabolic Disorders
  • 6.3.7. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Service
  • 7.1.1. Contract Manufacturing
    • 7.1.1.1. API Manufacturing
    • 7.1.1.2. Finished Product
      • 7.1.1.2.1. Solid Dosage Forms
      • 7.1.1.2.2. Injectables
      • 7.1.1.2.3. Others
    • 7.1.1.3. Packaging
  • 7.1.2. Contract Development
    • 7.1.2.1. Formulation Development
    • 7.1.2.2. Process Development & Scale-up
    • 7.1.2.3. Analytical Method Development & Validation
    • 7.1.2.4. Stability Testing
    • 7.1.2.5. CMC & Regulatory Development Support
    • 7.1.2.6. Others
• 7.2. Market Analysis, Insights and Forecast - By Molecule Type
  • 7.2.1. Small Molecules
  • 7.2.2. Biologics
  • 7.2.3. Cell & Gene Therapies
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 7.3.1. Oncology
  • 7.3.2. Infectious Diseases
  • 7.3.3. Neurology
  • 7.3.4. Cardiology
  • 7.3.5. Immunology & Inflammation
  • 7.3.6. Metabolic Disorders
  • 7.3.7. Others
• 7.4. Market Analysis, Insights and Forecast - By Countries/Sub-region
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of the Europe

8. Asia Pacific Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Service
  • 8.1.1. Contract Manufacturing
    • 8.1.1.1. API Manufacturing
    • 8.1.1.2. Finished Product
      • 8.1.1.2.1. Solid Dosage Forms
      • 8.1.1.2.2. Injectables
      • 8.1.1.2.3. Others
    • 8.1.1.3. Packaging
  • 8.1.2. Contract Development
    • 8.1.2.1. Formulation Development
    • 8.1.2.2. Process Development & Scale-up
    • 8.1.2.3. Analytical Method Development & Validation
    • 8.1.2.4. Stability Testing
    • 8.1.2.5. CMC & Regulatory Development Support
    • 8.1.2.6. Others
• 8.2. Market Analysis, Insights and Forecast - By Molecule Type
  • 8.2.1. Small Molecules
  • 8.2.2. Biologics
  • 8.2.3. Cell & Gene Therapies
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 8.3.1. Oncology
  • 8.3.2. Infectious Diseases
  • 8.3.3. Neurology
  • 8.3.4. Cardiology
  • 8.3.5. Immunology & Inflammation
  • 8.3.6. Metabolic Disorders
  • 8.3.7. Others
• 8.4. Market Analysis, Insights and Forecast - By Countries/Sub-region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia & New Zealand
  • 8.4.5. Rest of Asia Pacific

9. Rest of the World Contract Development & Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Service
  • 9.1.1. Contract Manufacturing
    • 9.1.1.1. API Manufacturing
    • 9.1.1.2. Finished Product
      • 9.1.1.2.1. Solid Dosage Forms
      • 9.1.1.2.2. Injectables
      • 9.1.1.2.3. Others
    • 9.1.1.3. Packaging
  • 9.1.2. Contract Development
    • 9.1.2.1. Formulation Development
    • 9.1.2.2. Process Development & Scale-up
    • 9.1.2.3. Analytical Method Development & Validation
    • 9.1.2.4. Stability Testing
    • 9.1.2.5. CMC & Regulatory Development Support
    • 9.1.2.6. Others
• 9.2. Market Analysis, Insights and Forecast - By Molecule Type
  • 9.2.1. Small Molecules
  • 9.2.2. Biologics
  • 9.2.3. Cell & Gene Therapies
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 9.3.1. Oncology
  • 9.3.2. Infectious Diseases
  • 9.3.3. Neurology
  • 9.3.4. Cardiology
  • 9.3.5. Immunology & Inflammation
  • 9.3.6. Metabolic Disorders
  • 9.3.7. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2024)
• 10.2. Company Profiles
  • 10.2.1. Lonza
  • 10.2.2. Thermo Fisher Scientific Inc.
  • 10.2.3. Catalent, Inc
  • 10.2.4. Samsung Biologics
  • 10.2.5. WuXi Biologics
  • 10.2.6. Siegfried Holding AG
  • 10.2.7. FUJIFILM Holdings Corporation
  • 10.2.8. Boehringer Ingelheim International GmbH
  • 10.2.9. Recipharm AB
  • 10.2.10. Cambrex Corporation